The maker of weight-loss drug Zepbound springs back into buy range.
Find The Best Stocks To Buy
Big Pharma Stock Eli Lilly Concocts New Buy Zone
Licensing
11:13 AM ET 06/08/2026
As the Nasdaq composite looks to rebound from Friday's sell-off, pharmaceutical giant Eli Lilly (LLY) has shown resilience, popping back into buy range. With its relative strength line on the rise, Eli Lilly stock has also secured a spot on the Investor's Business Daily Leaderboard, as well as the IBD Big Cap 20 and Stock Spotlight screens. On top of now…
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies - Eli Lilly (NYSE:
Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. The stock has rallied nearly 36% from recent…
Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity…
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and…
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
